SavedAdd your journal

Journals / Journal of Cell and Molecular Biology / 2002 / Cilt: 1 - Sayı: 2

FM3A hücrelerinin işaretlenme indeksi üzerine epirubisin ve tamoksifenin etkisi

Effect of epirubicin and tamowifen on labelling index in FM3A cells

Mehmet TOPÇUL
Atilla ÖZALPAN
Nevin ERENSOY
Özcan Gül ARICAN
Pages
81–85
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The findings reveal that treatments of epirubicin and tamoxifen lower the percentage of the cells at S phase, while combined treatment of epirubicin and tamoxifen gives more successful results, being statistically significant (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:C3H mouse mammary carsinoma-derived FM3A cell line grown in RPMI 1640+10%FBS medium as suspension culture have been used in tissue culture studies in recent years.
📊
Key Findings & Data:Changes in labelling index were examined in the present study, applying in vitro doses of epirubicin, tamoxifen and epirubicin+tamoxifen to FM3A cells.
💡
Conclusion & Impact:The findings reveal that treatments of epirubicin and tamoxifen lower the percentage of the cells at S phase, while combined treatment of epirubicin and tamoxifen gives more successful results, being statistically significant (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

C3H mouse mammary carsinoma-derived FM3A cell line grown in RPMI 1640+10%FBS medium as suspension culture have been used in tissue culture studies in recent years. Changes in labelling index were examined in the present study, applying in vitro doses of epirubicin, tamoxifen and epirubicin+tamoxifen to FM3A cells. The findings reveal that treatments of epirubicin and tamoxifen lower the percentage of the cells at S phase, while combined treatment of epirubicin and tamoxifen gives more successful results, being statistically significant (p

Özet

C3H fare meme karsinomu kökenli, RPMI 1640+%10 FBS içinde süspansiyon olarak kültüre edilmiş FM3A hücre soyu, son yıllarda doku kültürü çalışmalarında kullanılmaktadır. Bu çalışmada, FM3A hücreleri üzerine epirubisin, tamoksifen ve epirubisin+tamoksifenin in vitro dozları uygulanarak, işaretlenme indeksindeki değişimler incelenmiştir. Bulgular, epirubisin ve tamoksifen uygulamaları ile S fazındaki hücre yüzdelerinin düştüğünü, epirubisin ve tamoksifenin kombine uygulanmasının ise bu açıdan daha etkili ve istatistiksel olarak anlamlı (p

🔖

Cite This Article

TOPÇUL, M., ÖZALPAN, A., ERENSOY, N., ARICAN, Ö. G. (2022). FM3A hücrelerinin işaretlenme indeksi üzerine epirubisin ve tamoksifenin etkisi. Journal of Cell and Molecular Biology, Cilt: 1 - Sayı: 2, 81–85. https://ajindex.com/articles/560723

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Aglietta M, Monzeglio C, Pasquino P, Carnino F, Stern AC and Gavosto F. Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs. Cancer. 72: 2970-2973, 1993. Beatson GT. On the treatment of inoperable cases of carsinoma of mammal: Suggestions for a new method of treatment, with illustrative cases. Lancet. 2: 104- 107, 1896. Boccardo F, Rubagotti A, Bruzzi P, Cappellini M, Isola G, Nenci I, Piffanelli A, Scanni A, Sismondi P and Santi L. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor- positive breast cancer patients: Results of a multicentric Italian study. J Clin Oncol. 8: 1310- 1320, 1990.
  2. Cantoni O, Sestili P, Cattabeni F, Geroni C and Giuliani F. Comparative effects of doxorubicin and 4´- epidoxorubicin on nucleic acid metabolism and cytotoxicity in a human tumour cell line. Cancer Chemotherapy and Pharmacology. 27: 47-51, 1990.
  3. Clarke RB, Laidlaw IJ, Jones LJ, Howell A and Anderson E. Effect of tamoxifen on Ki67 labelling index in human breast tumours and it’s relationship to oestrogen progesterone receptor status. Br J Cancer. 67: 606- 11, 1993. Cuzick J and Baum M. Tamoxifen and contralateral breast cancer. Lancet (i). 282, 1985. Di marco A. Epirubicin: Mechanism of action at the cellular level. In: Advances in Anthracycline Chemotherapy. Epirubicin. Bonadonna G (Ed). Masson, Milano - Italia. 41-47, 1984.
  4. Douglas KT. Anticancer drugs, DNA-intercalation and free radical attack. Chemistry and Industry. 766-771, 1984.
  5. Greg L, Faulds P and Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs. 45: 788-856, 1993.
  6. Gullino PM, Pettigrew HN and Grantham FH. N- Nitrosomethylurea as mammary gland carcinogen in rats. J Natl Cancer Inst. 54: 401-414, 1975.
  7. Huggins SC, Grand LC and Brillantes FP. Mammary cancer, induced by a single feeding of polynuclear hydrocarbons and their suppression. Nature. 189: 204- 207, 1962. Lippman M and Huff KA. Demonstration of androgen and estrogen receptors in a human breast cancer using a new protamine sulfate assay. Cancer. 38: 868-874, 1976.
  8. Mc Guire WL, Horwitz KB, Zava DT, Garola RE and Chamness GC. Hormones in breast cancer: Update 1978. Metabolism. 27: 487-501, 1978.
  9. Mouridsen H, Palshof T, Paterson J and Battersby L. Tamoxifen in advanced breast cancer. Cancer Treat Rev. 5: 131-141, 1978. Murphy B and Muss HB. Hormon